Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis

Company Overview

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.22 to $8.16
• Volume: N/A
• Average Volume: 1,500 shs
• Market Capitalization: $1.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASPCF Stock Analysis - Frequently Asked Questions

How have ASPCF shares performed this year?

Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2025. Since then, ASPCF shares have increased by 0.0% and is now trading at $0.22.
View the best growth stocks for 2025 here.

When did Acerus Pharmaceuticals' stock split?

Acerus Pharmaceuticals shares reverse split on Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 3/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ASPCF
• CIK: N/A
• Web: www.aceruspharma.com
• Phone: (416) 679-0771
• Fax: 905-569-1809
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-33,820,000.00
• Net Margins: -924.33%
• Pretax Margin: -924.33%
• Return on Equity: N/A
• Return on Assets: -74.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.67
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $2.12 million
• Price / Sales: 0.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.38) per share
• Price / Book: -0.07

Miscellaneous

• Outstanding Shares: 7,708,000
• Free Float: N/A
• Market Cap: $1.70 million
• Optionable: Not Optionable
• Beta: 0.69